Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A vaccine study involving healthy adults

You are invited to take part in a study investigating a new vaccine against Respiratory Syncytial Virus (RSV).  The study is being run by the Oxford Vaccine Group which is part of the University of Oxford.

Please get in touch if you:

·      are aged 18 to 45 years old and in good health

·      are able to attend visits at the Churchill Hospital, Oxford

·      are interested in preventing a major cause of global infant deaths


We will provide reimbursement for your time, inconvenience and travel. The total study participation time is 1 year.


Before you decide whether you would like to take part, it is important for you to understand exactly what the study is about and what participation would involve.  If you would like to read more about the study and see if you are you eligible to take part, please go to here.


If you would like to discuss the study further, please contact us:

Telephone: 01865 857420

Email: info@ovg.ox.ac.uk

Similar stories

Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity

Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

Andrew Pollard writes about vaccine equity in his article for The Conversation.

Increasing vaccine uptake among ethnic minorities

Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.

Why we must expand newborn screening

Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.

Human challenge trial launches to study immune response to COVID-19

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Alternating vaccines trial expands to include two additional vaccines

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.